Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Paritaprevir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Paritaprevir SCHEMBL25744892 | 1.00 | CTSB (0.45) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| Paritaprevir SCHEMBL3061958 | 1.00 | CTSB (0.45) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| Paritaprevir SCHEMBL3061962 | 1.00 | CTSB (0.45) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| Paritaprevir SCHEMBL3069969 | 1.00 | CTSB (0.45) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| Paritaprevir SCHEMBL3069964 | 1.00 | CTSB (0.45) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| Paritaprevir SCHEMBL18713503 | 1.00 | CTSB (0.45) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| Paritaprevir SCHEMBL16541443 | 1.00 | CTSB (0.45) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| Paritaprevir SCHEMBL18923192 | 1.00 | CTSB (0.45) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| Paritaprevir SCHEMBL19286688 | 1.00 | CTSB (0.45) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| Paritaprevir SCHEMBL20145316 | 1.00 | CTSB (0.45) | CTSBADRB3ADRA2BADRA2CCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1265 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102345-A1 | METHODS OF ADMINISTERING THE VOLTAGE-GATED POTASSIUM CHANNEL OPENER AZETUKALNER | XENON PHARMACEUTICALS INC. (CA) | 2026-05-15 | — | — | WO | claimed |
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | BHAMIS RES LABORATORY PVT LTD (IN) | 2026-05-07 | — | — | US | claimed |
| WO-2026086804-A1 | MULTILAYER-REGULATED GENE EDITING SYSTEM AND USE THEREOF | 自如基因科技（深圳）有限公司 | 2026-04-30 | — | — | WO | claimed |
| US-20260102422-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-04-16 | — | — | US | claimed |
| EP-4719428-A1 | METHOD OF TREATING HEPATITIS C VIRUS IN PATIENTS | Altesa Biosciences, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| EP-4706636-A2 | A METHOD FOR CRYSTALLIZATION OF ACTIVE PHARMACEUTICAL INGREDIENTS | Nanoform Finland Oyj (FI) | 2026-03-11 | — | — | EP | claimed |
| US-12565665-B2 | Compositions and methods for controlled mRNA translation and stability | TRUSTEES OF BOSTON UNIVERSITY (US) | 2026-03-03 | — | — | US | claimed |
| CN-109689063-B | Alkyne-containing nucleotide and nucleoside therapeutic compositions and related uses thereof | 埃默里大学 | 2026-02-27 | — | — | CN | claimed |
| US-12533321-B2 | Polypeptide formulations for oral delivery | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2026-01-27 | — | — | US | claimed |
| EP-4680248-A1 | PRODUCTS OF MANUFACTURE AND THERAPEUTIC COMPOSITIONS FOR TREATING, AMELIORATING OR PREVENTING VIRAL INFECTIONS AND METHODS FOR MAKING AND USING THEM | Topelia Aust Limited (ACN 652 771 670) (AU) | 2026-01-21 | — | — | EP | claimed |
| WO-2022076386-A1 | COMPOSITIONS AND METHODS UTILIZING PROTEIN INHIBITORS FOR SYNERGISTIC INHIBITION AND TREATMENT OF SARS-COV-2 | MONTELIONE GAETANO THOMAS (US) | 2022-04-14 | — | — | WO | claimed |
| US-20220099672-A1 | Method for Treating and/or Preventing Bacteriophage Lysis During Fermentation | LOCUS SOLUTIONS, LLC | 2022-03-31 | — | — | US | claimed |
| US-20220098246-A1 | CHIMERIC ANTIGEN RECEPTOR (CAR) MODULATION | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-03-31 | — | — | US | claimed |
| US-20220090040-A1 | Fusion Constructs for Controlling Protein Function | SENTI BIOSCIENCES, INC. (US) | 2022-03-24 | — | — | US | claimed |
| US-20220088036-A1 | CONCOMITANT ADMINISTRATION OF GLUCOCORTICOID RECEPTOR MODULATORS AND CYP3A INHIBITORS | CORCEPT THERAPEUTICS, INC. | 2022-03-24 | — | — | US | claimed |
| EP-3969037-A2 | REGULATED SYNTHETIC GENE EXPRESSION SYSTEMS | Trustees of Boston University (US) | 2022-03-23 | — | — | EP | claimed |
| EP-3963087-A1 | IDENTIFICATION AND ANALYSIS OF MICROBIAL SAMPLES BY RAPID INCUBATION AND NUCLEIC ACID ENRICHMENT | Illumina Inc (US) | 2022-03-09 | — | — | EP | claimed |
| EP-3952841-A1 | DRUG ADSORBED HIGHLY POROUS ACTIVATED CARBON FOR ENHANCED DRUG DELIVERY | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2022-02-16 | — | — | EP | claimed |
| WO-2022029334-A1 | COMBINATION THERAPIES FOR TREATING CORONAVIRUS INFECTION | GBIOTECH S.À.R.L. (CH) | 2022-02-10 | — | — | WO | claimed |
| EP-3947432-A1 | CHIMERIC ANTIGEN RECEPTOR (CAR) MODULATION | Trustees of Boston University (US) | 2022-02-09 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102422-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | SARS1, ITK, SLC43A1 | CTSB 2518/4885ADRB3 1888/4885ADRA2B 3125/4885 |
| US-12533321-B2 | Polypeptide formulations for oral delivery | PTMS, IAPP, IGF1R | CTSB 3884/4885ADRB3 1217/4885ADRA2B 1703/4885 |
| US-12565665-B2 | Compositions and methods for controlled mRNA translation and stability | ADAR, ADA, NSUN2 | CTSB 4585/4885ADRB3 3872/4885ADRA2B 3039/4885 |
| US-20220098246-A1 | CHIMERIC ANTIGEN RECEPTOR (CAR) MODULATION | HAVCR2, CPB1, CTRL | CTSB 54/4885ADRB3 3737/4885ADRA2B 3371/4885 |
| US-20220088036-A1 | CONCOMITANT ADMINISTRATION OF GLUCOCORTICOID RECEPTOR MODULATORS AND CYP3A INHIBITORS | NR3C1, NR3C2, CYP3A43 | CTSB 3880/4885ADRB3 179/4885ADRA2B 383/4885 |
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | GLP1R, TTR, IAPP | CTSB 1295/4885ADRB3 1078/4885ADRA2B 1248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.